BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

AbbVie To Acquire Gilgamesh’s Lead Psychedelic Compound Bretisilocin For Up To $1.2 Billion

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of m...

August 26, 2025 | News

Asia Bio Innovation Summit 2025 Highlights ADC and CGT as Dual Engines of Biopharma Innovation

Asia Bio Innovation Summit 2025 is one of the premier industry-focused events in Asia and focus on the hottest topics of ADC and CGT. Asia B...

August 25, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

China’s Bio-Thera and Europe’s STADA Expand Biosimilars Alliance to Include Tocilizumab

Bio-Thera and STADA agree to extend their biosimilars alliance to cover tocilizumab, a targeted immunomodulatory monoclonal antibody directed against the...

August 25, 2025 | News

BioDlink Secures Indonesian Approval for Bevacizumab, Accelerating ASEAN and Global Expansion

BioDlink announced that its Bevacizumab Injection has obtained marketing authorization from Indonesia's National Agency of Drug and Food Con...

August 22, 2025 | News

Andelyn Biosciences Partners with Amplo Biotechnology to Advance AAV Gene Therapies for NMJ Disorders

Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered wi...

August 22, 2025 | News

Japan’s ARC Therapies Initiates Research on Novel Gut Microbe YB328 for Cancer Immunotherapy

ARC Therapies Inc. (Head Office: Shinjuku, Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Cente...

August 21, 2025 | News

Akeso Doses First Patient in Phase III COMPASSION-33 Trial of Cadonilimab for Perioperative Gastric Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-31...

August 21, 2025 | News

Somite.ai Secures Strategic Investment from AMD Ventures to Advance Foundation Models for Cell Therapy

Somite.ai, a company pioneering foundation models for human stem cells, announced a strategic investment from AMD Ventures, following Somite's $...

August 21, 2025 | News

Thermo Fisher Launches Gibco™ Expi293™ PRO System to Transform Protein Expression

Thermo Fisher Scientific has introduced the Gibco™ Expi293™ PRO Expression System, a next-generation HEK293 transient expression system designe...

August 20, 2025 | News

Mabwell Secures FDA IND Clearance for CDH17-Targeting ADC 7MW4911 in Advanced GI Cancers

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...

August 20, 2025 | News

South Korea’s GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Plasma-Derived Medicines Workforce in Thailand

GC Biopharma , a South Korean biopharmaceutical company, announced that it has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Soc...

August 19, 2025 | News

Everest Medicines’ Etrasimod (VELSIPITY®) Receives Strong Recommendation in Updated ACG Clinical Guideline for Ulcerative Colitis

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

August 18, 2025 | News

Novo Nordisk’s Wegovy® Becomes First and Only GLP-1 Therapy Approved for MASH with Moderate to Advanced Fibrosis

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with modera...

August 18, 2025 | News

Stay Connected